Theravance Biopharma’s (TBPH) “Buy” Rating Reaffirmed at BTIG Research

Theravance Biopharma (NASDAQ:TBPH)‘s stock had its “buy” rating reiterated by BTIG Research in a research note issued on Tuesday,Benzinga reports. They currently have a $40.00 target price on the biopharmaceutical company’s stock. BTIG Research’s target price points to a potential upside of 101.71% from the stock’s previous close.

Several other research firms also recently weighed in on TBPH. HC Wainwright increased their price target on Theravance Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Wall Street Zen lowered shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Oppenheimer began coverage on shares of Theravance Biopharma in a research note on Wednesday, December 3rd. They issued an “outperform” rating and a $27.00 target price for the company. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $27.80.

Theravance Biopharma Stock Up 4.7%

Theravance Biopharma stock opened at $19.83 on Tuesday. The firm has a 50 day moving average price of $19.05 and a 200-day moving average price of $15.75. Theravance Biopharma has a twelve month low of $7.90 and a twelve month high of $21.03. The company has a market capitalization of $1.00 billion, a P/E ratio of 34.79 and a beta of 0.15.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.10. Theravance Biopharma had a net margin of 36.53% and a return on equity of 12.20%. The company had revenue of $19.99 million for the quarter, compared to analysts’ expectations of $19.89 million. Equities analysts expect that Theravance Biopharma will post -1.09 EPS for the current fiscal year.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total value of $582,506.25. Following the sale, the senior vice president directly owned 277,695 shares in the company, valued at $5,206,781.25. This represents a 10.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Quarry LP bought a new stake in Theravance Biopharma during the third quarter valued at $26,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 1,411 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Theravance Biopharma by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 515 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 781 shares during the last quarter. Finally, CIBC Private Wealth Group LLC grew its holdings in shares of Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 4,662 shares in the last quarter. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.